HC Wainwright Reiterates Buy Rating for Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 135.73% from the stock’s previous close. SMMT has been […]
More Stories
7 Best Bespoke Smoke Vents for Large and Complex Roof Openings (2026)
Picture a main contractor in Leeds coordinating a logistics warehouse where the structural grid leaves a 2,800 mm clear zone...
6 College Football Teams Generating the Most Betting Interest in 2026
Three weeks into the 2026 college football season, several familiar contenders are already shaping national conversations. Early results have shifted...
Nobody Wants This Season 3: Release Date, Cast Members, and Episodes
Nobody Wants This season 3 is coming back soon! It is an American romantic comedy series. The series first premiered...
6 Companies Delivering Innovative Data Center Cooling Technologies
Data Center Cooling Technologies are no longer a nice-to-have. They’re what separates a facility running at peak performance from one...
Top DevOps Testing Tools for Faster Software Delivery in 2026
Most teams don’t have a testing problem. They have a speed problem. DevOps Testing Tools promise faster feedback loops, but...
Long Story Short Season 2 Is Renewed! Release Date, Plot, and More
Netflix has recently given anime fans a major reason to celebrate by renewing Long Story Short for a new season....